Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size, Share and Global Trend By Drug Type (Corticosteroids, Immunoglobulin, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2024-2032

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder leading to weakness and loss of sensation in legs and arms. It occurs due to the improper reaction of the body’s immune system and damaging myelin sheath. Myelin sheath surrounds the peripheral nerves system and acts as an insulator for the nerves to conduct impulses properly. Symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) includes tingling, numbness or altered feeling, which often begins in hand and feet, weakness in arms and legs, fatigue, muscle pain, and others.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is more prominently observed in men than in women. The active government support through awareness programs and drug approvals is expected to positively impact the global chronic inflammatory demyelinating polyneuropathy therapeutics market. Furthermore, the FDA approval for Hizentra, a subcutaneous immunoglobulin manufactured by CSL Behring in March 2018, is estimated to accelerate the demand for chronic inflammatory demyelinating polyneuropathy drugs.

The rising prevalence of chronic inflammatory demyelinating polyneuropathy increased R&D spending, and strategic research collaborations between pharmaceutical industries are the factors attributed to the growth in the global chronic inflammatory demyelinating polyneuropathy therapeutics market.

Also, active government support in creating awareness about rare neurological diseases and the expected launch of potential pipeline drugs candidates are anticipated to further fuel the global chronic inflammatory demyelinating polyneuropathy therapeutics market. For example, Pfizer Inc. has initiated the phase 1 clinical study for PF-06755347, a recombinant immunomodulatory drug candidate for the treatment of chronic inflammatory demyelinating polyneuropathy.

However, high pricing of the approved drugs and presence of limited treatment options are the major factors that can restrain the growth in the global chronic inflammatory demyelinating polyneuropathy therapeutics market.

Key Players Covered

Some of the major companies that are present in the global chronic inflammatory demyelinating polyneuropathy therapeutics market are CSL Behring, ADMA Biologics, Grifols, S.A., Shire, Pfizer Inc., GeNeuro SA, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, AbbVie, Inc., Mitsubishi Tanabe Pharma Corporation, and others.

SEGMENTATION

Based of drug type, the immunoglobulin segment is anticipated to have exponential growth in the global chronic inflammatory demyelinating polyneuropathy therapeutics market over the forecast period owing to the new product launch, rapid adoption of both intravenous and subcutaneous immunoglobulins for the treatment of chronic inflammatory demyelinating polyneuropathy, and emerging government guidelines.

Key Insights

• Prevalence of chronic inflammatory demyelinating polyneuropathy for key countries
• The regulatory scenario for key countries
• New product launch
• Pipeline analysis
• Patent Snapshot
• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America is projected to dominate the global chronic inflammatory demyelinating polyneuropathy therapeutics market in the forecast duration owing to the increase in incidence and prevalence of the chronic inflammatory demyelinating polyneuropathy. According to the CIDP Foundation International, chronic inflammatory demyelinating polyneuropathy (CIDP) affects about 8.9% per 100,000 people every year in North America, which is likely to propel the growth of global chronic inflammatory demyelinating polyneuropathy therapeutics market. Europe and Asia Pacific are expected to register a considerable growth rate owing to the active government support, developing healthcare infrastructure, and growing emphasis by healthcare organizations and government towards the development of the new therapeutics on chronic inflammatory demyelinating polyneuropathy.

Key Industry Developments

• In March 2018, CSL Behring received FDA approval for Hizentra, a subcutaneous immunoglobulin for the treating chronic inflammatory demyelinating polyneuropathy.
• In February 2018, GeNeuro SA received Orphan Drug Designation (ODD) for the company’s drug candidates for chronic inflammatory demyelinating polyneuropathy (CIDP) from the FDA.
• In 2019, UCB S.A initiated phase 2 clinical trials for Rozanolixizumab for the treatment of patients with chronic inflammatory demyelinating polyneuropathy.
• Pfizer Inc. initiated the phase 1 clinical study for PF-06755347, a recombinant immunomodulatory drug candidate for the treatment of chronic inflammatory demyelinating polyneuropathy.